[15] Russo A, Franchina T, Ricciardi G, et al. Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future pers...
EGFR背景介绍 EGFR(Epidermal Growth Factor Receptor,表皮生长因子受体)是一种跨膜受体酪氨酸激酶,属于ErbB受体家族(又称HER家族)。EGFR在多种细胞类型中表达,主要通过与其配体结合,诱导受体二聚化(同源或异源二聚化),激活其酪氨酸激酶活性,启动下游信号通路,调控多种细胞生物学功能调控细胞的增殖、分化、迁移和存活...
在肺腺癌中，EGFR突变（酪氨酸激酶这个关键部件可以自己激活）导致细胞不需要外界信号就可以自己说了算，细胞就疯长。有些病人与家属可能知道TKI这么回事。那么TKI是什么呢，Tyrosine kinase inhabitor （酪氨酸激酶抑制剂）。EGFR的靶向药就是这样一种抑制剂。我说了这么多，还是不通俗。举个例子吧，唐玄宗时期，受中...
[16]Mok T, Nakagawa K, Park K, et al. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase In...
Costa DB. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors. Lung Cancer. 2023 Jul;181:107250. doi: 10.1016/j.lungcan....
2021年3月2日,Jens Meiler & Christine M. Lovly团队在期刊《Nature communications》(IF:14.919)上发表了题为“Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting”的文章,描述了ERBB家族KDD在多种人类癌症中...
[4]Robichaux JP,Elamin YY,Tan Z,et al.Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.Nat Med.2018;24(5):638-646.doi:10.1038/s41591-018-0007-9. [5]Piotrowska Z,Wang Y,Sequist LV,et al.ECOG-ACRIN 5162:a phase...
[20]Lu S, Wu L, Jian H, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-15): second interim analysis from a double-blind, randomised, placebo-controlled, ...
Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, Xia YZ, Kong LY. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. Pharmacol Res. 2021 May;167:105583. ...
[7]Costa DB. Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements. Transl Lung Cancer Res. 2016 Jun;5(3):331-7. doi: 10.21037/tlcr.2016.06.04. ...